UFP Technologies Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by UFP Technologies, Inc. on August 26, 2024. The filing discloses the completion of a strategic acquisition under Item 7.01 (Regulation FD Disclosure).
Key Financial Metrics and Transaction Details
- Transaction: Acquisition of all issued and outstanding shares of the parent holding companies of AQF Limited (operating as AQF Medical).
- Target Profile: A leading manufacturer of custom engineered foam and thermoplastic components headquartered in County Meath, Ireland.
- Purchase Price: €43.0 million in cash.
- Valuation Multiple: Approximately 12.3 times AQF Medical's adjusted EBITDA for the 12-month period ended June 30, 2024.
- Other Metrics: The filing does not provide specific revenue, profit, cash flow, or debt figures for UFP Technologies or AQF Medical beyond the transaction valuation multiple.
Material Changes
The primary material change is the expansion of UFP's operations into the Irish market through the acquisition of AQF Medical. The transaction was finalized pursuant to a Share Purchase Agreement dated August 23, 2024.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) containing forward-looking statements regarding the acquisition. Management notes that actual results may differ materially from these statements due to risks and uncertainties. The filing includes a standard limitation on incorporation by reference, stating that the information in Item 7.01 is not deemed "filed" under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the exact closing date and final purchase price of the AQF Medical acquisition.
- Review the attached press release (Exhibit 99.1) for detailed forward-looking statements and strategic rationale.
- Confirm the impact of the €43.0 million cash outlay on UFP's current liquidity and debt covenants.
- Assess the integration timeline and expected synergies from the acquisition of the Irish-based manufacturer.